Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors

Cancer Research

Volumn 63, Issue 1, 2003, Pages 250-255

  Tsuiki, Hiromasa ^a   Tnani, Mehdi ^a   Okamoto, Isamu ^a   Kenyon, Lawrence C ^a   Emlet, David R ^a   Holgado Madruga, Marina ^a   Lanham, Irene S ^a   Joynes, Christopher J ^a   Vo, Kim T ^a   Wong, Albert J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GREEN FLUORESCENT PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CARCINOGENESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; GLIOMA; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TWO DIMENSIONAL ELECTROPHORESIS;

EID: 0037224587     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Davis, R. J. Signal transduction by the JNK group of MAP kinases. Cell. 103: 239-252, 2000.
2. Ip, Y. T., and Davis, R. J. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr. Opin. Cell Biol., 10: 205-219, 1998.
3. Minden, A., and Karin, M. Regulation and function of the JNK subgroup of MAP kinases. Biochim. Biophys. Acta, 1333: F85-F104, 1997.
4. Gupta, S., Barrett, T., Whitmarsh, A. J., Cavanagh, J., Sluss, H. K., Derijard, B., and Davis, R. J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J., 15: 2760-2770, 1996.
5. Raitano, A. B., Halpern, J. R., Hambuch, T. M., and Sawyers, C. L. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. USA, 92: 11746-11750, 1995.
6. Rodrigues, G. A., Park, M., and Schlessinger, J. Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J., 16: 2634-2645, 1997.
7. Xu, X., Heidenreich, O., Kitajima, I., McGuire, K., Li, Q., Su, B., and Nerenberg, M. Constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis. Oncogene, 13: 135-142, 1996.
8. Bost, F., McKay, R., Dean, N., and Mercola, D. The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells. J. Biol. Chem., 272: 33422-33429, 1997.
9. Coffey, E. T., Smiciene, G., Hongisto, V., Cao, J., Brecht, S., Herdegen, T., and Courtney, M. J. c-Jun N-terminal protein kinase (JNK) 2/3 is specifically activated by stress, mediating c-Jun activation, in the presence of constitutive JNK1 activity in cerebellar neurons. J. Neurosci., 22: 4335-4345, 2002.
10. Antonyak, M. A., Moscatello, D. K., and Wong, A. J. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J. Biol. Chem., 273: 2817-2822, 1998.
11. Arbour, N., Naniche, D., Homann, D., Davis, R. J., Flavell, R. A., and Oldstone, M. B. c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8(+) T cell-mediated antiviral immunity. J. Exp. Med., 195: 801-810, 2002.
12. Bost, F., McKay, R., Bost, M., Potapova, O., Dean, N. M., and Mercola, D. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol. Cell. Biol., 19: 1938-1949, 1999.
13. Chen, N., Nomura, M., She, Q. B., Ma, W. Y., Bode, A. M., Wang, L., Flavell, R. A., and Dong, Z. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res., 61: 3908-3912, 2001.
14. Conze, D., Krahl, T., Kennedy, N., Weiss, L., Lumsden, J., Hess, P., Flavell, R. A., Le Gros, G., Davis, R. J., and Rincon, M. c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation. J. Exp. Med., 195: 811-823, 2002.
15. Kuan, C. Y., Yang, D. D., Samanta Roy, D. R., Davis, R. J., Rakic, P., and Flavell, R. A. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron, 22: 667-676, 1999.
16. Potapova, O., Gorospe, M., Bost, F., Dean, N. M., Gaarde, W. A., Mercola, D., and Holbrook, N. J. c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J. Biol. Chem., 275: 24767-24775, 2000.
17. Antonyak, M. A., Kenyon, L. C., Godwin, A. K., James, D. C., Emlet, D. R., Okamoto, I., Tnani, M., Holgado-Madruga, M., Moscatello, D. K., and Wong, A. J. Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene, 21: 5038-5046, 2002.
18. Moscatello, D. K., Montgomery, R. B., Sundareshan, P., McDanel, H., Wong, M. Y., and Wong, A. J. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene, 13: 85-96, 1996.
19. Tsuiki, H., Nitta, M., Furuya, A., Hanai, N., Fujiwara, T., Inagaki, M., Kochi, M., Ushio, Y., Saya, H., and Nakamura, H. A novel human nucleoside diphosphate (NDP) kinase, Nm23-H6, localizes in mitochondria and affects cytokinesis. J. Cell. Biochem., 76: 254-269, 1999.
20. Okamoto, I., Tsuiki, H., Kenyon, L. C., Godwin, A. K., Emlet, D. R., Holgado-Madruga, M., Lanham, I. S., Joynes, C. J., Vo, K. T., Guha, A., Matsumoto, M., Ushio, Y., Saya, H., and Wong, A. J. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am. J. Pathol., 160: 441-447, 2002.
21. Tsuiki, H., Nitta, M., Tada, M., Inagaki, M., Ushio, Y., and Saya, H. Mechanism of hyperploid cell formation induced by microtubule inhibiting drug in glioma cell lines. Oncogene, 20: 420-429, 2001.
22. Sivaraman, V. S., Wang, H., Nuovo, G. J., and Malbon, C. C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Investig., 99: 1478-1483, 1997.
23. Xing, C., and Imagawa, W. Altered MAP kinase (ERK1, 2) regulation in primary cultures of mammary tumor cells: elevated basal activity and sustained response to EGF. Carcinogenesis (Lond.), 20: 1201-1208, 1999.
24. Mandell, J. W., Hussaini, I. M., Zecevic, M., Weber, M. J., and VandenBerg, S. R. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am. J. Pathol., 153: 1411-1423, 1998.
25. Hoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., Shimada, Y., Ari-i, S., Wada, H., Fujimoto, J., and Kohno, M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene, 18: 813-822, 1999.
26. Wong, A. J., Zoltick, P. W., and Moscatello, D. K. The molecular biology and molecular genetics of astrocytic neoplasms. Semin. Oncol., 21: 139-148, 1994.
27. Fleming, Y., Armstrong, C. G., Morrice, N., Paterson, A., Goedert, M., and Cohen, P. Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. Biochem. J., 352: 145-154, 2000.
28. Finch, A., Davis, W., Carter, W. G., and Saklatvala, J. Analysis of mitogen-activated protein kinase pathways used by interleukin 1 in tissues in vivo: activation of hepatic c-Jun N-terminal kinases 1 and 2 and mitogen-activated protein kinase kinases 4 and 7. Biochem. J., 353: 275-281, 2001.
29. Theodosiou, A., and Ashworth, A. Differential effects of stress stimuli on a JNK-inactivating phosphatase, Oncogene, 21: 2387-2397, 2002.
30. Todd, J. L., Rigas, J. D., Rafty, L. A., and Denu, J. M. Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK). Oncogene, 21: 2573-2583, 2002.
31. Maroney, A. C., Glicksman, M. A., Basma, A. N., Walton, K. M., Knight, E., Jr., Murphy, C. A., Bartlett, B. A., Finn, J. P., Angeles, T., Matsuda, Y., Neff, N. T., and Dionne, C. A. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J. Neurosci., 18: 104-111, 1998.
32. Maroney, A. C., Finn, J. P., Connors, T. J., Durkin, J. T., Angeles, T., Gessner, G., Xu, Z., Meyer, S. L., Savage, M. J., Greene, L. A., Scott, R. W., and Vaught, J. L. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem., 276: 25302-25308, 2001.